Justin Walsh
Stock Analyst at Jones Trading
(1.85)
# 3,087
Out of 4,868 analysts
38
Total ratings
37.14%
Success rate
-8.51%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNRX VolitionRx | Initiates: Buy | $3 | $0.67 | +346.96% | 1 | Jun 10, 2025 | |
| BLRX BioLineRx | Upgrades: Buy | $12 | $4.57 | +162.58% | 3 | May 30, 2025 | |
| CLNN Clene | Initiates: Buy | $30 | $4.37 | +586.50% | 1 | Apr 23, 2025 | |
| MNPR Monopar Therapeutics | Downgrades: Hold | n/a | $33.00 | - | 1 | Apr 2, 2025 | |
| LNTH Lantheus Holdings | Maintains: Buy | $127 → $122 | $78.99 | +54.45% | 8 | Mar 21, 2025 | |
| SER Serina Therapeutics | Initiates: Buy | $11 | $5.75 | +91.30% | 1 | Mar 11, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $18 | $2.27 | +692.95% | 1 | Dec 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $11.02 | +281.13% | 1 | Oct 18, 2024 | |
| THTX Theratechnologies | Downgrades: Hold | n/a | $2.50 | - | 2 | Oct 11, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $23 | $4.63 | +396.76% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $3.45 | +537.68% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.50 | +190.91% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.14 | +536.94% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $4 | $1.16 | +244.83% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.80 | +1,011.11% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $0.21 | +8,311.21% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $440 | $1.53 | +28,658.17% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $0.20 | +36,937.04% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $31.52 | -36.55% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $2.30 | +8,595.65% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.38 | +320.17% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $800 | $5.54 | +14,340.43% | 1 | Sep 2, 2021 |
VolitionRx
Jun 10, 2025
Initiates: Buy
Price Target: $3
Current: $0.67
Upside: +346.96%
BioLineRx
May 30, 2025
Upgrades: Buy
Price Target: $12
Current: $4.57
Upside: +162.58%
Clene
Apr 23, 2025
Initiates: Buy
Price Target: $30
Current: $4.37
Upside: +586.50%
Monopar Therapeutics
Apr 2, 2025
Downgrades: Hold
Price Target: n/a
Current: $33.00
Upside: -
Lantheus Holdings
Mar 21, 2025
Maintains: Buy
Price Target: $127 → $122
Current: $78.99
Upside: +54.45%
Serina Therapeutics
Mar 11, 2025
Initiates: Buy
Price Target: $11
Current: $5.75
Upside: +91.30%
Alto Neuroscience
Dec 16, 2024
Initiates: Buy
Price Target: $18
Current: $2.27
Upside: +692.95%
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $11.02
Upside: +281.13%
Theratechnologies
Oct 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.50
Upside: -
Y-mAbs Therapeutics
Jul 11, 2024
Initiates: Buy
Price Target: $23
Current: $4.63
Upside: +396.76%
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $3.45
Upside: +537.68%
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $5.50
Upside: +190.91%
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $3.14
Upside: +536.94%
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $1.16
Upside: +244.83%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $1.80
Upside: +1,011.11%
May 16, 2023
Initiates: Buy
Price Target: $18
Current: $0.21
Upside: +8,311.21%
Feb 10, 2023
Initiates: Buy
Price Target: $440
Current: $1.53
Upside: +28,658.17%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $0.20
Upside: +36,937.04%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $31.52
Upside: -36.55%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $2.30
Upside: +8,595.65%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $2.38
Upside: +320.17%
Sep 2, 2021
Initiates: Buy
Price Target: $800
Current: $5.54
Upside: +14,340.43%